Lv2
120 积分 2023-08-10 加入
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
19小时前
待确认
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
20小时前
已完结
HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade
1个月前
已完结
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers
2个月前
已完结
Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates
3个月前
已完结
A critical look at HLA-G
3个月前
已完结
A single inhibitor for all KRAS mutations
3个月前
已完结
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
4个月前
已完结
The target atlas for antibody-drug conjugates across solid cancers
5个月前
已完结
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
6个月前
已完结
皖公网安备34019202002308
